Research programme: serotonin 1F receptor agonists - Eli Lilly/Lundbeck

Drug Profile

Research programme: serotonin 1F receptor agonists - Eli Lilly/Lundbeck

Alternative Names: LY 418094

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Lundbeck Research USA
  • Class
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 01 Mar 2017 CoLucid Pharmaceuticals has been acquired by Eli Lilly
  • 22 Feb 2006 No development reported - Preclinical for Migraine in USA (unspecified route)
  • 17 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top